Accretion Nutraveda IPO Opens Today; Price Band Set at ₹122 to ₹129 Per Share 

Mumbai, 28 January 2026: The ₹24.77 Accretion Nutraveda IPO opens today, 28 January 2026, for subscription. The IPO is entirely a fresh issue of 0.19 crore shares, and will be opened till 30 January 2026 for subscription. 

Established in 2021, Accretions Nutraveda is a Manufacturer for Ayurvedic and Nutraceutical products in variou͏s dosage forms, including ͏tablets, capsules, oral liquids, powders, oils, and external preparations such as balms, creams, and gels.  

The company ope͏rates as a CDMO (Contract Development and Manufacturing Organization) serving both domestic and international markets, including Sri Lanka, Singapore, and the USA. Its products com͏bine classical Ayurvedic principles with modern nutraceutical science to address ͏areas such as liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.  

Accretion Nutraveda IPO Price Band Set Between ₹122 and ₹129 Per Share; Lot Size 1000 Shares 

Accretion Nutraveda IPO is a book build issue of ₹24.77 crore. The issue is entirely a fresh issue of 0.19 crore shares of ₹24.77 crore. 

Accretion Nutraveda IPO opens today, January 28, 2026, for subscription and closes on Jan 30, 2026. The allotment for the Accretion Nutraveda IPO is expected to be finalised on February 2, 2026, with shares expected to list on the BSE SME on February 4, 2026. 

Accretion Nutraveda IPO price band is set at ₹122 to ₹129 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,58,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹3,87,000. 

Sobhagya Capital Options Pvt. Ltd is the book running lead manager, and Kfin Technologies Ltd. is the registrar of the issue. The Market Maker of the company is Sunflower Broking Pvt. Ltd. 

Accretion Nutraveda IPO Reservation and Anchor Investors 

Accretion Nutraveda IPO offers a total of 19,20,000 shares. Out of which 9,08,000 (47.29%) has been allocated to QIB, 3,62,000 (18.85%) to QIB (Ex- Anchor), 2,76,000 (14.37%) to NII, 6,40,000 (33.33%) to RII and 5,46,000 (28.44%) allocated to Anchor investors. 

Accretion Nutraveda raised ₹7.04 crore from anchor investors on January 27, 2026. Key anchor investors include Unicorn Fund and Radiant Global Fund Class B Participating Shares. 

Utilisation of Proceeds 

Accretion Nutraveda proposes to utilise the net Proceeds from the issue towards purchase of machineries for automation in existing manufacturing unit (₹4.22 crore), purchase of machineries for the new manufacturing setup (₹8.03 crore), funding working capital requirements (₹5.50 crore), and meeting general corporate expenses 

Accretion Nutraveda IPO Key Financials 

The Company has exhibited consistent growth in recent periods. As of 30 September 2025, the assets increased from ₹4.06 crore in March 2023 to ₹16.35 crore, and the net worth went up significantly to ₹8.26 crore. Total revenue soared to ₹16.06 crore in March 2025 against ₹3.07 crore in March 2023. Net profit after tax stood at ₹2.33 crore, aided by EBITDA of ₹3.29 crore. The borrowings however increased slightly due to growth and the reserves were fortified in general. Reserves and surplus became positive, indicating higher profitability and overall better balance sheet stability position.  

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.  

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.  

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations